RECTOR DAVID 4
4 · Sevion Therapeutics, Inc. · Filed Dec 21, 2017
Insider Transaction Report
Form 4
RECTOR DAVID
Director
Transactions
- Award
Common Stock Option (Right to Buy)
2017-12-19+27,500→ 27,500 totalExercise: $6.00From: 2017-12-19Exp: 2027-12-19→ Common Stock (27,500 underlying)
Footnotes (1)
- [F1]Such options were granted to Mr. Rector under Sevion Therapeutics Inc.'s ("Sevion's") 2008 Incentive Compensation Plan for services performed during Sevion's fiscal year ended June 30, 2017 and the portion of Sevion's fiscal year ended June 30, 2018 leading up to the closing of Sevion's transaction with Eloxx Pharmaceuticals, Ltd. (the "Transaction"), which occurred on December 19, 2017. In connection with the closing of the Transaction, Sevion effected a 1-for-20 reverse stock split and changed its corporate name to "Eloxx Pharmaceuticals, Inc." Such options were granted on a post-split basis and are immediately exercisable at an exercise price of $6.00 per share, which is equal to the closing selling price of Sevion's common stock on December 19, 2017, as reflected on a post-split basis.